MacroGenics is discontinuing the development of vobramitamab duocarmazine (vobra duo) after disappointing results in a Phase II study for prostate cancer.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
MacroGenics is discontinuing the development of vobramitamab duocarmazine (vobra duo) after disappointing results in a Phase II study for prostate cancer.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing